Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Sep 1;111(9):882-886.
doi: 10.1093/jnci/djz076.

Recruitment and Trial-Finding Apps-Time for Rules of the Road

Review

Recruitment and Trial-Finding Apps-Time for Rules of the Road

Stephanie R Morain et al. J Natl Cancer Inst. .

Abstract

The problem of insufficient recruitment to clinical oncology trials is well known. Some stakeholders view mobile apps as a solution with the potential to make recruitment more efficient, lower trial costs, support patient-centeredness, and accelerate treatment advances. Recruitment and trial-finding apps seek to disrupt the traditional approach to recruitment in several ways, including aggregating information about ongoing trials and presenting it in a user-friendly format, curating information to tailor search results to prospective participants' interests, facilitating direct contact between prospective participants and trial sites, and, in at least one case, analyzing individuals' tumor samples and medical records to provide tailored recommendations both for approved treatments and clinical trials. Although recruitment and trial-finding apps respond to a real need, they raise ethical concerns. Here, we outline six domains of ethical concern: review of recruitment materials, privacy and confidentiality, constrained choice and conflicts of interest, therapeutic misbranding, payment for accessing research-related information, and disruptions to care and research. We offer several suggestions and encourage additional dialogue to improve the ethical acceptability of these apps because, as third parties increasingly promise to revolutionize clinical trial recruitment by connecting patients and investigators via recruitment and trial-finding apps, we need some rules of the road.

PubMed Disclaimer

References

    1. Institute of Medicine. A National Cancer Clinical Trials System for the 21st Century. Washington, DC: National Academies Press; 2010. - PubMed
    1. Unger JM, Vaidya R, Hershman DL, Minasian LM, Fleury ME.. Systematic review and meta-analysis of the magnitude of structural, clinical, and physician and patient barriers to cancer clinical trial participation. J Natl Cancer Inst. 2019;111(3):245–255. doi:10.1093/jnci/djy221. - PMC - PubMed
    1. Sung NS, Crowley WF Jr, Genel M, et al. Central challenges facing the national clinical research enterprise. JAMA. 2003;28910:1278–1287. - PubMed
    1. Kasenda B, von Elm E, You J, et al. Prevalence, characteristics, and publication of discontinued randomized trials. JAMA. 2014;31110:1045–1052. - PubMed
    1. Haidich AB, Ioannidis JP.. Effect of early patient enrollment on the time to completion and publication of randomized controlled trials. Am J Epidemiol. 2001;1549:873–880. 10.1093/aje/154.9.873. - PubMed